R3 Vascular

Focus: R3 Vascular develops bioresorbable, coated scaffolds for peripheral artery disease (PAD), a specialized cardiovascular device play. The company is newly public (founded 2024) and based in Mountain View, CA.

Cardiovascular

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Funding Stage

PUBLIC

Total Funding

$300M

Open Jobs

About R3 Vascular

AI assessmentNot Hiring

No open roles listed right now. Follow R3 Vascular to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

3 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

MAGNITUDE Sirolimus-eluting Bioresorbable Scaffold

Chronic Limb-Threatening Ischemia

N/A

Clinical Trials (1)

NCT06071429Bioresorbable Sirolimus-Eluting Scaffold Treatment for Below the Knee Disease

N/A

Help build intelligence for R3 Vascular

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage public company with focused technology platform in high-unmet-need cardiovascular space (PAD affects millions globally)
Ground-floor opportunity to build organizational infrastructure and culture at a newly public entity
Proprietary bioresorbable scaffold technology with differentiated mechanism vs. traditional stents

Watch Out For

No active job openings currently listed, suggesting early-stage hiring or potential organizational uncertainty post-IPO
Minimal publicly available clinical data (zero active trials reported) raises questions about development stage and near-term catalysts
Newly public status (2024) means unproven business execution and cash runway risk despite public funding

Generated by Claude from R3 Vascular's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

MAGNITUDE BRS

Critical Limb-Threatening Ischemia

N/A

Clinical Trials (1)

NCT06075940Evaluation of the MAGNITUDE® Bioresorbable Drug-Eluting Scaffold in the Treatment of Patients With Below the Knee Disease in Australia

N/A

Percutaneous Implantation of the MAGNITUDE® Bioresorbable Arterial Scaffold

Peripheral Arterial Disease

N/A

Clinical Trials (1)

NCT04912323Study of the R3 Vascular Drug-Eluting Bioresorbable Scaffold in Treating Below the Knee Arterial Disease

N/A

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2024

Portfolio: 3 clinical trials

Top TAs: Cardiovascular

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Cardiovascular

1 pipeline

Marketed

Pipeline